Home / Stock ratings / GLP-1, Obesity and Biotech Stocks / GILD
Stock rating · Biological Products, (No Diagnostic Substances)
Gilead Sciences Inc (GILD) Stock Rating & Analysis
As of October 6, 2026, MELANY rates Gilead Sciences Inc 73 out of 100 (Highest Conviction). Its highest factor score is catalyst setup at 94, and its lowest is valuation at 49.
MELANY ratingRated 2026-10-06GILD · composite score
About Gilead Sciences Inc
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with its portfolio centered on HIV and hepatitis B and C. Its acquisition of Pharmasset brought the hepatitis C drug Sovaldi, now part of newer standard-of-care combination regimens, and it is expanding in oncology, led by the CAR-T cell therapy Yescarta/Tecartus (from Kite) and the breast and bladder cancer therapy Trodelvy (from Immunomedics).
Rating as of 2026-10-06 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
Why GILD scores 73/100
GILD's 8 factor scores run from 49 to 94, and 3 of them sit above its composite of 73. Here is how GILD breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
Margins, returns on capital, and balance-sheet strength.
- Gross margin 79%
Direction and relative strength of the recent share-price trend.
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
- Avg EPS beat +7%
- Earnings in 23 days (strong beat history)
What Wall Street price targets and revisions are signalling.
- Institutional net buying +4.1%
Near-term events that could move the stock.
- Earnings in 23 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How GILD compares
As of October 7, 2026, Gilead Sciences Inc is tied for 1st of 20 in GLP-1, Obesity and Biotech Stocks, where the average score is 64.
Also ranked in Healthcare Stocks. All stock rating pages.
Key risks for GILD
- High debt-to-equity ratio 2.2x, rate-sensitive balance sheet
- No positive trailing earnings, valuation cannot be anchored to current P/E
Sector and theme context
Gilead Sciences Inc sits in the Healthcare sector theme, which MELANY currently rates 37/100 for strength. Theme strength feeds GILD's momentum and catalyst factors above.
GILD trade plan (Pro)
MELANY has a full position plan for Gilead Sciences Inc: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates GILD
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Gilead Sciences Inc's 73/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about GILD
Is Gilead Sciences Inc (GILD) a buy?
As of 2026-10-06, MELANY rated Gilead Sciences Inc Highest Conviction with a composite score of 73/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Gilead Sciences Inc's MELANY score?
Gilead Sciences Inc (GILD) has a MELANY composite score of 73/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the GILD stock rating calculated?
MELANY scores GILD from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Gilead Sciences Inc stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Gilead Sciences Inc (GILD) Highest Conviction with a composite of 73/100 as of 2026-10-06. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the GILD stock price forecast?
MELANY does not publish price targets or forecasts for GILD. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 73/100 across eight factors for Gilead Sciences Inc, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is GILD stock overvalued or undervalued?
MELANY's valuation factor currently reads 49/100 for Gilead Sciences Inc, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives GILD's read.
What price should I buy GILD at?
Rather than chasing the current price, MELANY computes a smart entry zone for GILD: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying GILD stock?
The top risks MELANY currently flags for Gilead Sciences Inc: High debt-to-equity ratio 2.2x, rate-sensitive balance sheet; No positive trailing earnings, valuation cannot be anchored to current P/E. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Gilead Sciences Inc a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 56/100 for Gilead Sciences Inc, and earnings track record, at 81/100. The 73/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will GILD stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 58/100 for GILD right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this GILD rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-06. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores GILD continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, GILD included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.